PT - JOURNAL ARTICLE AU - Toledo-Romani, M. Eugenia AU - Garcia-Carmenate, M. AU - Silva, C. Valenzuela AU - Baldoquin-Rodriguez, W. AU - Pérez, M. Martínez AU - Rodríguez Gonzalez, M. C. AU - Moreno, B. Paredes AU - Mendoza Hernández, I. C. AU - Romero, R. González-Mujica AU - Tabio, O. Samón AU - Velazco Villares, P. M. AU - Bacallao Castillo, J. P. AU - Martín, E. Licea AU - Rodríguez Ortega, M. AU - Herrera Marrero, N. L. AU - Gonzalez, E. Caballero AU - Egües Torres, L. I. AU - González, R. Duarte AU - Blanco, S. García AU - Cabrera, S. Pérez AU - Ferreira, S. Huete AU - Cisnero, K. Idalmis AU - Galindo, O. Fonte AU - Pérez, D. Meliá AU - Remedios, I. Rojas AU - Castillo, S. Fernandez AU - Ruiz, Y. Climent AU - Valdes-Balbin, Y. AU - Garcia-Rivera, D. AU - Bencomo, V. Verez AU - , TI - Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination AID - 10.1101/2021.10.31.21265703 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.31.21265703 4099 - http://medrxiv.org/content/early/2021/11/06/2021.10.31.21265703.short 4100 - http://medrxiv.org/content/early/2021/11/06/2021.10.31.21265703.full AB - Background SOBERANA 02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phase 1 and 2 clinical trials demonstrated its high immunogenicity, promoting neutralizing IgG and specific T-cell response. A third dose, of SOBERANA Plus (RBD-dimer), further increased the specific anti-RBD neutralizing antibodies.Methods In a randomized, double-blind, placebo-controlled, phase-3 trial (https://rpcec.sld.cu/trials/RPCEC00000354-En) we randomly assigned 44 031 participants, aged 19–80 years to three groups to receive a) two doses, SOBERANA 02, or b) two doses, SOBERANA 02 and a third dose, SOBERANA Plus, or c) placebo. Study endpoints are vaccine efficacy (VE) evaluated through confirmed symptomatic COVID-19 and safety. During the trial, the SARS CoV-2 isolates in Havana were 74.0 % β, shifting gradually to 100% δ.Results Two doses of SOBERANA 02 protected against symptomatic COVID-19: 43 cases in the two-dose group (14 371) vs. 155 in the placebo group (14 403), VE 71.0%, adjusted (CI 95%, 58.9–79.1). The heterologous three-dose combination increased the protection: 15 cases in the vaccine groups (13 833) vs. 155 in the placebo group (14 303), VE 92.4%, adjusted (CI 95%, 86.9–95.6%). For the two-dose schedule, VE against severe COVID-19 was 63.0% and for death, 59.0%; for the heterologous three-dose schedule, VE was 100% in both cases.Conclusions This is the first phase-3 study of a three-dose, heterologous COVID-19 vaccine. Two doses of SOBERANA 02 were safe and attained efficacy of 71.0% in the adult population 19-80 y/o; incorporating SOBERANA Plus increased efficacy from 71.0 % to 92.4%.Competing Interest Statement(M. M. P, M. C. R. G., B. P. M., R. G.M. R., E. L. M., E.C.G., S. F., Y. C., Y. V.B., D. G.R., V. V. B.) are from Finlay Vaccine Institute the sponsor of the trialClinical TrialRPCEC00000354 International Clinical Trials Registry Platform. IdentifierFunding StatementSupported by Finlay Vaccine Institute, Biocubafarma and by Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Central Research Ethics Committee from the Cuban Ministry of Health was ad hoc appointed for this trial. They approved the protocol (Clinical Trials IFV/COR/09 number, RPCEC00000354) and the consent forms.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://rpcec.sld.cu/en/trials/RPCEC00000354-En